Pune, 8, Dec, 2022: Maximize Market research, a global healthcare market research firm, based out of India, has published a competitive intelligence and market research report on Chronic Kidney Disease Drugs Market Market size was valued at USD 11.78 Bn. in 2021 and the total Chronic Kidney Disease (CKD) Drugs revenue is expected to grow by 5.6% from 2022 to 2029, reaching nearly USD 18.21 Bn.
Chronic Kidney Disease Drugs Market Scope and Research Methodology
As per the scope of this report, chronic kidney disease is a condition that causes reduced kidney working efficiency over a period of time. The chronic kidney disease drug market is segmented by drug class (ACE inhibitors, angiotensin-II receptor blockers, diuretics, and other treatment products), end user (hospital, Speciality clinics), other end user and region (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments. The report offers the value (in USD million) for the above segments.
The bottom-up approach was employed to validate the market size in terms of value and volume by different segments. Data was collected employing both primary and secondary data collection methods. Surveys, administering questionnaires and telephonic interviews with industry specialists, market leaders, entrepreneurs and marketing professionals were included in the primary methods. Secondary data was collected from a list of sources for maximum reliability of the inferences. This includes official databases of various organisations and government sites, industry journals, white papers, annual reports, releases of product manufacturers and suppliers in the industry along with paid databases.
SWOT analysis was conducted to provide the strengths and weaknesses of Chronic Kidney disease drug Market while PESTLE was employed to understand the potential impact of the micro-economic factors affecting the automotive advanced driver assistance systems Market. Thus the report provides a detailed overview of the Chronic Kidney disease drug Market.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @all https://www.maximizemarketresearch.com/request-sample/39171
Chronic Kidney Disease Drugs Market Overview
Chronic kidney disease occurs when the kidneys get damaged and are unable to work with full efficency and cannot filter blood properly. Patients may experience difficulties related to fluid, electrolytes and waste build-up as a result to poor filtration. And it may cause to kidney failure. Over 15% of adults in the United States, nearly 37 million individuals are expected to have CKD. As per statistics, one out of every 10 persons has chronic renal disease. The CKD is growing global and is expected to become the fifth leading cause of death in year by 2040. The growth in kidney illnesses, as well as the rising need for effective pharmaceuticals for curing this disease are some of the primary drivers driving the growth of the chronic kidney disease (CKD) drug market.
Chronic Kidney Disease Drugs Market Dynamics
Kidney failure is a global public health issue with rising patients and prevalence, high expenditures, and poor results. There is also a much greater frequency of chronic kidney disease (CKD) in its early stages, with negative effects such as renal function loss, cardiovascular disease (CVD), and premature mortality. CKD affects over one-third of the diabetic population and is the leading cause of end-stage kidney failure. According to the WHO statistics in 2019, around 1.13 million people all across the globe have hypertension. Diabetes and hypertension were responsible for about 75% of kidney failure. Diabetes is the main cause of severe kidney disease, followed by hypertension. As a result, the growing number of individuals suffering from hypertension and diabetes is driving the chronic kidney disease drugs market growth.
Medication dosing errors is one of most common issue with chronic kidney disease. As many medications, drugs and their metabolites are done through kidney. And to avoid toxicity, proper renal function is important.
Chronic Kidney Disease Drugs Market Regional Insights
North America held the largest share in 2021 and it is expected to maintain same position during forecast period. As per American Cancer Society near about 73,750 new occurrences of kidney cancer in the United States in 2020, with roughly 14,830 fatalities from this illness.
As per some source, kidney cancer is one of the top 10 cancers in both men and women. The market in the United States is expected to grow during the forecast period due to the significant growth in the patients and prevalence of renal illnesses.
The Asia Pacific have the highest revenue share of more than 24.00% because of increased spending on healthcare, various government initiatives & awareness campaigns related with CKD, availability of advanced drugs, and the presence of newly-established advance healthcare facilities in the region. High blood pressure and diabetes are the two most common causes of renal damage. The Asia Pacific region is expected to have the most diabetes and hypertension sufferers in the global, closely followed by Africa.
Chronic Kidney Disease Drugs Market Segmentation
By Drug Class
- ACE Inhibitors
- Angiotensin-II Receptor Blockers
- Calcium Channel Blockers
- Beta Blockers
- Erythropoiesis-Stimulating Agents (Esas)
- Diuretics
- Others
By End User
- Hospitals
- Specialty Clinics
By region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Chronic Kidney Disease Drugs Market Key Manufacturers include:
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- AbbVie, Inc.
- GlaxoSmithKline plc.
- Sanofi S.A.
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- AstraZeneca plc
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Allergan plc.
- FibroGen
- Johnson & Johnson
- Akebia Therapeutics, Inc.
- Novo Nordisk AS
- KBP BioSciences Co Ltd
- Pharmaxis Ltd
- Astellas Pharma Inc.
- IC-MedTech Inc.
- Allena Pharmaceuticals Inc.
- NovaTarg Therapeutics Inc.
- KBP BioSciences Co Ltd.
- OPKO Health Inc.
- Les Laboratoires Servier SAS
- Kidney Fibrosis
- Q BioMed Inc
- Unity Biotechnology Inc.
- Boryung Pharmaceutical Co Ltd.
- Taisho Pharmaceutical Holdings Co Ltd.
- DiaMedica Therapeutics Inc.
For Detail insights on this market, request for methodology here @ https://www.maximizemarketresearch.com/request-sample/39171
Key questions answered in the Chronic Kidney Disease Drugs Market are:
- What is chronic kidney disease drug?
- What is the growth rate of chronic kidney disease drug Market for the next five years?
- What is the nature of competition in chronic kidney disease drug industry in developed and developing economies?
- Who are the key players in the chronic kidney disease drug Market?
- Who are the market leaders in chronic kidney disease drug in Europe
- Who are the market leaders in chronic kidney disease drug in USA and Canada
- Who are the market leaders in chronic kidney disease drug in India, China, Japan and South Korea?
- What are the factors affecting growth in the chronic kidney disease drug Market?
- Who held the largest market share in chronic kidney disease drug Market?
- What are the factors for the growth of Asia-Pacific region in chronic kidney disease drug market?
Key Offerings:
- Market Share, Size & Forecast by Revenue | 2022−2029
- Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Key Trends
- Market Segmentation – A detailed analysis by drug class, end user and region
- Competitive Landscape – Top Key Vendors and Other Prominent Vendors
Maximize Market Research is leading healthcare & life science firm, has also published the following reports:
Asthma Treatment Market: Asthma Treatment Market size is expected to grow at a CAGR of 4.27% during the forecast period and the market size is expected to reach nearly US$ 28.15 Bn. by 2029. External and internal factors which supposed to affect business in positive and negative manner are analysed, which will provide a clear picture of industry to the decision makers.
Sarcoma Drugs Market: Sarcoma Drugs Market size was valued at USD 759.2 Mn. in 2021 and the total Sarcoma Drugs revenue is expected to grow by 23 % from 2022 to 2029, reaching nearly USD 1405.3 Mn. In recent years prescription drug prices have been rapidly growing. This has resulted in an increase in overall healthcare spending.
Aesthetics Injectable Market: Aesthetics Injectable Market was valued nearly US$ 12.95 Bn in 2021. Aesthetics Injectable Market size is estimated to grow at a CAGR of 8.76 % & is expected to reach at US$ 23.31Bn by 2027. The market is growing due to increasing in the number of facial treatments and rising demand for aesthetic procedures.
About Maximize Market Research:
Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041, India
sales@maximizemarketresearch.com
+91 96071 95908, +91 9607365656
Media Contact
Company Name: MAXIMIZE MARKET RESEARCH PVT. LTD.
Contact Person: Geeta Yevle
Email: Send Email
Address:3rd Floor, Navale IT Park, Phase 2, Pune Banglore Highway, Narhe,
City: Pune
State: Maharashtra
Country: India
Website: https://www.maximizemarketresearch.com/market-report/global-chronic-kidney-disease-ckd-drugs-market/39171/